Reviewed By
Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 20 Researches
7.4
USERS' SCORE
Good
Based on 5 Reviews
8.3
Supplement Facts
Serving Size: 2 Softgels
Amount Per Serving
%DV
Calories
20
Total Fat
2 g
3%**
Saturated Fat
0.5 g
3%**
Polyunsaturated Fat
1 g
†
Monounsaturated Fat
0.5 g
†
Fish Oil Concentrate
2 g (2,000 mg)
†
Eicosapentaenoic Acid (EPA)
360 mg
†
Docosahexaenoic Acid (DHA)
240 mg
†
Top Medical Research Studies
9
We focused on how Maresin 1, a compound derived from docosahexaenoic acid, might help improve iron-deficient anemia in mice with chronic colitis. Our research involved IL-10 knockout mice, which are known to develop spontaneous colitis and associated anemia.
Over two weeks, we treated these mice with MaR1, observing several important changes. We found that MaR1 significantly reduced inflammation in the colon and was associated with a boost in hemoglobin levels, increased serum iron, and improved transferrin saturation.
Additionally, we noted that the levels of hepcidin, a protein that regulates iron metabolism and is often elevated during inflammation, decreased after treatment. This suggests that MaR1 helps combat anemia by influencing this protein's expression through the IL-6/STAT3 pathway.
Overall, we uncovered promising evidence that MaR1 has the potential to alleviate anemia connected to inflammatory processes, making it a noteworthy area for further exploration in treating patients with similar conditions.
Over two weeks, we treated these mice with MaR1, observing several important changes. We found that MaR1 significantly reduced inflammation in the colon and was associated with a boost in hemoglobin levels, increased serum iron, and improved transferrin saturation.
Additionally, we noted that the levels of hepcidin, a protein that regulates iron metabolism and is often elevated during inflammation, decreased after treatment. This suggests that MaR1 helps combat anemia by influencing this protein's expression through the IL-6/STAT3 pathway.
Overall, we uncovered promising evidence that MaR1 has the potential to alleviate anemia connected to inflammatory processes, making it a noteworthy area for further exploration in treating patients with similar conditions.
Read More
8
We explored how a treatment called SC411, which is enriched with eicosapentaenoic acid (EPA), impacts anemia in a specific mouse model of sickle cell disease (SCD). SCD often leads to severe anemia and other serious health issues. Our investigation revealed that SC411 increased the levels of both docosahexaenoic acid (DHA) and EPA in the blood, which are essential fatty acids known to have beneficial effects on health.
Furthermore, we observed that SC411 helped decrease harmful arachidonic acid levels and reduced the sickling of red blood cells, thereby potentially alleviating some of the pain and complications associated with the disease. The treatment not only improved cerebral blood flow but also seemed to enhance cognitive functions, like memory, in the mice.
Overall, the results highlighted that treatment with SC411 could significantly enhance survival rates in mice with SCD through improved cellular and functional outcomes, paving the way for new therapeutic strategies to handle ischemic injuries related to this debilitating condition.
Furthermore, we observed that SC411 helped decrease harmful arachidonic acid levels and reduced the sickling of red blood cells, thereby potentially alleviating some of the pain and complications associated with the disease. The treatment not only improved cerebral blood flow but also seemed to enhance cognitive functions, like memory, in the mice.
Overall, the results highlighted that treatment with SC411 could significantly enhance survival rates in mice with SCD through improved cellular and functional outcomes, paving the way for new therapeutic strategies to handle ischemic injuries related to this debilitating condition.
Read More
8
We explored how eicosapentaenoic acid (EPA) relates to anemia in patients with sickle cell disease (SCD). The study compared blood fatty acids in 43 individuals with homozygous sickle cell disease (HbSS) to 43 healthy controls.
Our analysis revealed that patients with SCD had higher levels of certain n-6 fatty acids, but notably lower amounts of EPA and docosahexaenoic acid (DHA). Interestingly, we found a positive correlation between the steady-state hemoglobin levels and the presence of DHA and EPA in the red blood cell membranes of the patients. These findings suggest that incorporating EPA and DHA into their diets could help improve anemia.
This imbalance in fatty acids highlights a potential area for dietary intervention. By correcting this imbalance through supplementation, we might improve the health of individuals affected by this condition.
Our analysis revealed that patients with SCD had higher levels of certain n-6 fatty acids, but notably lower amounts of EPA and docosahexaenoic acid (DHA). Interestingly, we found a positive correlation between the steady-state hemoglobin levels and the presence of DHA and EPA in the red blood cell membranes of the patients. These findings suggest that incorporating EPA and DHA into their diets could help improve anemia.
This imbalance in fatty acids highlights a potential area for dietary intervention. By correcting this imbalance through supplementation, we might improve the health of individuals affected by this condition.
Read More
Most Useful Reviews
7.5
Improved anaemia management
4 people found this helpful
I began using Now supplements for my overall health. As a CKD sufferer, I must be cautious with the supplements I take. I can confidently say these have significantly improved my condition, especially concerning the anaemia associated with CKD. The pills are easy to swallow, offer great value, and have no discernible taste.
Read More
9
Normalised anaemia levels
2 people found this helpful
I take one tablet each morning and evening. After six months of use, my anaemia has returned to normal. I'm combining this oil with multivitamins as recommended, and it seems to be working well.
Read More
9
Improved health readings
I have no complaints about this product. After taking Omega-3, my slight anaemia post-COVID improved significantly, with my haemoglobin levels approaching normal. I appreciate this brand's products and continue to take two tablets after breakfast.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 20 Researches
7.4
- All Researches
9
We examined the effectiveness of eicosapentaenoic acid (EPA) in preventing anemia caused by ribavirin during hepatitis C treatment. This study involved twelve chronic hepatitis C patients, aged between 3 and 21 years, who were divided into two groups: one receiving EPA and the other acting as a control. Blood samples were collected at various intervals to monitor changes in hemoglobin levels and ribavirin concentrations throughout the treatment period.
Our findings revealed that those who received EPA experienced significantly less reduction in hemoglobin levels compared to the control group. In fact, by weeks eight and sixteen, the protective effects against anemia were clear and statistically significant. While we did not observe any notable differences in ribavirin drug levels between the two groups, one patient in the control group had to lower their ribavirin dosage due to anemia.
Overall, our research underscores the potential of EPA supplementation as a preventative measure against ribavirin-related anemia in young patients undergoing treatment for hepatitis C. This offers a promising strategy to improve treatment adherence and outcomes for this vulnerable population.
Our findings revealed that those who received EPA experienced significantly less reduction in hemoglobin levels compared to the control group. In fact, by weeks eight and sixteen, the protective effects against anemia were clear and statistically significant. While we did not observe any notable differences in ribavirin drug levels between the two groups, one patient in the control group had to lower their ribavirin dosage due to anemia.
Overall, our research underscores the potential of EPA supplementation as a preventative measure against ribavirin-related anemia in young patients undergoing treatment for hepatitis C. This offers a promising strategy to improve treatment adherence and outcomes for this vulnerable population.
Read More
9
We focused on how Maresin 1, a compound derived from docosahexaenoic acid, might help improve iron-deficient anemia in mice with chronic colitis. Our research involved IL-10 knockout mice, which are known to develop spontaneous colitis and associated anemia.
Over two weeks, we treated these mice with MaR1, observing several important changes. We found that MaR1 significantly reduced inflammation in the colon and was associated with a boost in hemoglobin levels, increased serum iron, and improved transferrin saturation.
Additionally, we noted that the levels of hepcidin, a protein that regulates iron metabolism and is often elevated during inflammation, decreased after treatment. This suggests that MaR1 helps combat anemia by influencing this protein's expression through the IL-6/STAT3 pathway.
Overall, we uncovered promising evidence that MaR1 has the potential to alleviate anemia connected to inflammatory processes, making it a noteworthy area for further exploration in treating patients with similar conditions.
Over two weeks, we treated these mice with MaR1, observing several important changes. We found that MaR1 significantly reduced inflammation in the colon and was associated with a boost in hemoglobin levels, increased serum iron, and improved transferrin saturation.
Additionally, we noted that the levels of hepcidin, a protein that regulates iron metabolism and is often elevated during inflammation, decreased after treatment. This suggests that MaR1 helps combat anemia by influencing this protein's expression through the IL-6/STAT3 pathway.
Overall, we uncovered promising evidence that MaR1 has the potential to alleviate anemia connected to inflammatory processes, making it a noteworthy area for further exploration in treating patients with similar conditions.
Read More
9
DHA improves RBC flexibility in anemia
We explored the impact of docosahexaenoic acid (DHA), a type of omega-3 fatty acid, on red blood cells (RBCs) in mice with sickle cell disease (SCD). The research focused on whether DHA could improve RBC stiffness and deformability, which are crucial factors in anemia related to SCD.
To conduct our study, sickle cell mice were given diets with either 3% DHA or a control diet rich in total fat for eight weeks. We used advanced methods to assess the stiffness and flexibility of the RBCs, along with analyzing blood smears for the presence of irreversibly sickled RBCs.
Our findings were quite striking. We observed that the mice consuming the DHA diet showed significantly improved RBC flexibility and a reduction in the number of irreversibly sickled cells by approximately 40%, compared to those on the control diet. This suggests that DHA supplementation may have therapeutic potential in enhancing RBC function and potentially alleviating some symptoms of anemia in sickle cell disease.
Overall, our study underscores the role of dietary omega-3 fatty acids like DHA in managing conditions associated with rigid and sickled red blood cells. While more research is needed to fully understand the implications, these results offer a promising perspective on dietary interventions for sickle cell disease.
To conduct our study, sickle cell mice were given diets with either 3% DHA or a control diet rich in total fat for eight weeks. We used advanced methods to assess the stiffness and flexibility of the RBCs, along with analyzing blood smears for the presence of irreversibly sickled RBCs.
Our findings were quite striking. We observed that the mice consuming the DHA diet showed significantly improved RBC flexibility and a reduction in the number of irreversibly sickled cells by approximately 40%, compared to those on the control diet. This suggests that DHA supplementation may have therapeutic potential in enhancing RBC function and potentially alleviating some symptoms of anemia in sickle cell disease.
Overall, our study underscores the role of dietary omega-3 fatty acids like DHA in managing conditions associated with rigid and sickled red blood cells. While more research is needed to fully understand the implications, these results offer a promising perspective on dietary interventions for sickle cell disease.
Read More
We explored the effectiveness of adding omega-3 fish oil, specifically its components eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), along with Manuka honey, to conventional therapies in treating oxidative stress in children with β-thalassemia major. In this study, 165 pediatric patients were involved in a randomized, double-blind trial. They were divided into three groups: one received a combination of omega-3 and Manuka honey, while another group got just Manuka honey, and a third group followed standard treatment alone.
Throughout the ten-month study period, we measured various markers of oxidative stress and overall health in these children. Our findings revealed that the combination of omega-3 and Manuka honey showed more effectiveness in managing oxidative stress than either Manuka honey alone or the conventional treatment. This suggests that integrating omega-3 into their treatment plan could offer better outcomes for managing the health challenges associated with β-thalassemia.
Ultimately, our research highlights the potential role of omega-3 as a beneficial component in the treatment of anemia related to oxidative stress in pediatric patients. By addressing both oxidative stress and iron overload, we hope this approach leads to improved management strategies for young individuals dealing with this inherited condition.
Throughout the ten-month study period, we measured various markers of oxidative stress and overall health in these children. Our findings revealed that the combination of omega-3 and Manuka honey showed more effectiveness in managing oxidative stress than either Manuka honey alone or the conventional treatment. This suggests that integrating omega-3 into their treatment plan could offer better outcomes for managing the health challenges associated with β-thalassemia.
Ultimately, our research highlights the potential role of omega-3 as a beneficial component in the treatment of anemia related to oxidative stress in pediatric patients. By addressing both oxidative stress and iron overload, we hope this approach leads to improved management strategies for young individuals dealing with this inherited condition.
Read More
8
Eicosapentaenoic acid improves anemia
We explored how eicosapentaenoic acid (EPA), a type of omega-3 fatty acid, influences anemia in mice suffering from tuberculosis (TB). The study compared two groups of mice with different levels of omega-3 fatty acids—one with a low status and another with a sufficient status. After being infected with TB, both groups were given additional EPA to see its impact alongside standard TB medications.
After 14 days of treatment, we observed that mice with low omega-3 levels showed improved hemoglobin levels compared to untreated mice with sufficient omega-3. Specifically, the low omega-3 group had higher hemoglobin, meaning they were potentially less anemic.
Furthermore, our findings revealed that the low omega-3 mice experienced lower levels of pro-inflammatory cytokines, which are markers for inflammation, indicating that EPA may help in reducing inflammation as well. This suggests that EPA can offer a dual benefit by improving anemia and mitigating inflammation during TB treatment, particularly in individuals who start with low omega-3 levels.
After 14 days of treatment, we observed that mice with low omega-3 levels showed improved hemoglobin levels compared to untreated mice with sufficient omega-3. Specifically, the low omega-3 group had higher hemoglobin, meaning they were potentially less anemic.
Furthermore, our findings revealed that the low omega-3 mice experienced lower levels of pro-inflammatory cytokines, which are markers for inflammation, indicating that EPA may help in reducing inflammation as well. This suggests that EPA can offer a dual benefit by improving anemia and mitigating inflammation during TB treatment, particularly in individuals who start with low omega-3 levels.
Read More
User Reviews
USERS' SCORE
Good
Based on 5 Reviews
8.3
- All Reviews
- Positive Reviews
- Negative Reviews
7.5
Improved anaemia management
4 people found this helpful
I began using Now supplements for my overall health. As a CKD sufferer, I must be cautious with the supplements I take. I can confidently say these have significantly improved my condition, especially concerning the anaemia associated with CKD. The pills are easy to swallow, offer great value, and have no discernible taste.
Read More
9
Normalised anaemia levels
2 people found this helpful
I take one tablet each morning and evening. After six months of use, my anaemia has returned to normal. I'm combining this oil with multivitamins as recommended, and it seems to be working well.
Read More
9
Improved health readings
I have no complaints about this product. After taking Omega-3, my slight anaemia post-COVID improved significantly, with my haemoglobin levels approaching normal. I appreciate this brand's products and continue to take two tablets after breakfast.
Read More
7.5
Reduced hair fallout
2 people found this helpful
Having undergone hair straightening eight years ago, my hair became brittle and began to fall out excessively, particularly due to my anaemia and iron deficiency. After two months of taking Omega-3 and Gold C, I was pleasantly surprised by the significant reduction in hair fallout. Although I haven't noticed improvements in my skin, my hair has begun to recover.
Read More
7.5
Decreased anaemia symptoms
After taking this supplement for two months, I have noticed a reduction in signs of anaemia. I plan to continue using it in the future.
Read More
Frequently Asked Questions
7.5
Decreased anaemia symptoms
After taking this supplement for two months, I have noticed a reduction in signs of anaemia. I plan to continue using it in the future.
7.5
Improved anaemia management
4 people found this helpful
I began using Now supplements for my overall health. As a CKD sufferer, I must be cautious with the supplements I take. I can confidently say these have significantly improved my condition, especially concerning the anaemia associated with CKD. The pills are easy to swallow, offer great value, and have no discernible taste.
9
Normalised anaemia levels
2 people found this helpful
I take one tablet each morning and evening. After six months of use, my anaemia has returned to normal. I'm combining this oil with multivitamins as recommended, and it seems to be working well.
9
Improved health readings
I have no complaints about this product. After taking Omega-3, my slight anaemia post-COVID improved significantly, with my haemoglobin levels approaching normal. I appreciate this brand's products and continue to take two tablets after breakfast.
7.5
Reduced hair fallout
2 people found this helpful
Having undergone hair straightening eight years ago, my hair became brittle and began to fall out excessively, particularly due to my anaemia and iron deficiency. After two months of taking Omega-3 and Gold C, I was pleasantly surprised by the significant reduction in hair fallout. Although I haven't noticed improvements in my skin, my hair has begun to recover.
7
Eicosapentaenoic acid aids anemia management
We conducted a study to explore how eicosapentaenoic acid (EPA) could help manage anemia that often occurs with ribavirin treatment in patients with chronic hepatitis C. In this randomized controlled trial, we analyzed 100 patients, dividing them into two groups: one receiving EPA along with their ribavirin and pegylated interferon-alpha treatment, and the other receiving only the standard therapy.
By week 12, we observed that a smaller percentage of patients in the EPA group needed to lower their ribavirin doses compared to those in the non-EPA group. Specifically, 17% of patients taking EPA experienced dose reduction, in contrast to 29% in the control group, indicating that EPA may help maintain the original ribavirin dosage.
Although the reduction in hemoglobin levels and ribavirin plasma concentrations were similar across both groups, our analysis revealed that the use of EPA significantly influenced the likelihood of avoiding ribavirin dose reductions. These findings suggest that incorporating EPA could be beneficial for patients in the early stages of hepatitis C treatment, but we recognize that further large-scale studies are necessary to confirm these results.
By week 12, we observed that a smaller percentage of patients in the EPA group needed to lower their ribavirin doses compared to those in the non-EPA group. Specifically, 17% of patients taking EPA experienced dose reduction, in contrast to 29% in the control group, indicating that EPA may help maintain the original ribavirin dosage.
Although the reduction in hemoglobin levels and ribavirin plasma concentrations were similar across both groups, our analysis revealed that the use of EPA significantly influenced the likelihood of avoiding ribavirin dose reductions. These findings suggest that incorporating EPA could be beneficial for patients in the early stages of hepatitis C treatment, but we recognize that further large-scale studies are necessary to confirm these results.
8
Eicosapentaenoic acid improves anemia
We explored how eicosapentaenoic acid (EPA), a type of omega-3 fatty acid, influences anemia in mice suffering from tuberculosis (TB). The study compared two groups of mice with different levels of omega-3 fatty acids—one with a low status and another with a sufficient status. After being infected with TB, both groups were given additional EPA to see its impact alongside standard TB medications.
After 14 days of treatment, we observed that mice with low omega-3 levels showed improved hemoglobin levels compared to untreated mice with sufficient omega-3. Specifically, the low omega-3 group had higher hemoglobin, meaning they were potentially less anemic.
Furthermore, our findings revealed that the low omega-3 mice experienced lower levels of pro-inflammatory cytokines, which are markers for inflammation, indicating that EPA may help in reducing inflammation as well. This suggests that EPA can offer a dual benefit by improving anemia and mitigating inflammation during TB treatment, particularly in individuals who start with low omega-3 levels.
After 14 days of treatment, we observed that mice with low omega-3 levels showed improved hemoglobin levels compared to untreated mice with sufficient omega-3. Specifically, the low omega-3 group had higher hemoglobin, meaning they were potentially less anemic.
Furthermore, our findings revealed that the low omega-3 mice experienced lower levels of pro-inflammatory cytokines, which are markers for inflammation, indicating that EPA may help in reducing inflammation as well. This suggests that EPA can offer a dual benefit by improving anemia and mitigating inflammation during TB treatment, particularly in individuals who start with low omega-3 levels.
7
We conducted a phase 2 study to investigate the effect of docosahexaenoic acid (DHA) treatment on anemia in children with sickle cell disease (SCD). In this double-blind, randomized, multicenter trial, 67 children aged 5 to 17 received either SC411, a specialized DHA formulation, or a placebo for four to eight weeks.
Our findings indicated that all doses of SC411 significantly increased DHA levels in the blood, which is promising. We also observed noteworthy changes in D-dimer and soluble E-selectin levels after eight weeks for those on a 36 mg/kg dose. Specifically, there was a significant increase in hemoglobin levels in participants receiving 20 mg DHA/kg compared to the placebo group.
Although participants reported a reduction in sickle cell crises and pain medication usage, the overall decrease in clinical episodes compared to the placebo did not achieve statistical significance. Nevertheless, the treatment was safe, with no major adverse effects reported.
In summary, while we observed some potential benefits of DHA on hemoglobin levels and inflammation, the clinical impact on anemia isn’t definitive, especially given that many participants were also on hydroxyurea. As we continue to explore these findings, it highlights the complexity of treating anemia in SCD.
Our findings indicated that all doses of SC411 significantly increased DHA levels in the blood, which is promising. We also observed noteworthy changes in D-dimer and soluble E-selectin levels after eight weeks for those on a 36 mg/kg dose. Specifically, there was a significant increase in hemoglobin levels in participants receiving 20 mg DHA/kg compared to the placebo group.
Although participants reported a reduction in sickle cell crises and pain medication usage, the overall decrease in clinical episodes compared to the placebo did not achieve statistical significance. Nevertheless, the treatment was safe, with no major adverse effects reported.
In summary, while we observed some potential benefits of DHA on hemoglobin levels and inflammation, the clinical impact on anemia isn’t definitive, especially given that many participants were also on hydroxyurea. As we continue to explore these findings, it highlights the complexity of treating anemia in SCD.
4
We investigated how eicosapentaenoic acid (EPA), a type of omega-3 fatty acid, affects anemia in mice infected with tuberculosis (TB). In our study, mice were given diets with either iron, EPA, or a combination of both for three weeks after infection. Our findings revealed that both iron and EPA supplementation led to lower inflammation levels in the body and improved anemia separately.
Specifically, we noticed that mice treated with EPA had reduced levels of certain inflammatory markers and lower bacterial loads in their lungs, suggesting that EPA can help with inflammation and potentially lower the negative impacts of infection. However, when we combined EPA with iron, these beneficial effects seemed to be less effective.
Overall, our study suggests that while EPA can positively impact anemia brought on by TB, combining it with iron might not enhance its benefits. So, EPA on its own shows promise for managing anemia and reducing inflammation in TB infections, but the combination with iron could complicate these positive effects.
Specifically, we noticed that mice treated with EPA had reduced levels of certain inflammatory markers and lower bacterial loads in their lungs, suggesting that EPA can help with inflammation and potentially lower the negative impacts of infection. However, when we combined EPA with iron, these beneficial effects seemed to be less effective.
Overall, our study suggests that while EPA can positively impact anemia brought on by TB, combining it with iron might not enhance its benefits. So, EPA on its own shows promise for managing anemia and reducing inflammation in TB infections, but the combination with iron could complicate these positive effects.
References
- Gamaleldin M, Abraham I, Meabed M, Elberry A, Abdelhalim S, et al. Comparative effectiveness of adding omega-3 and Manuka honey combination to conventional therapy in preventing and treating oxidative stress in pediatric β-thalassemia major - a randomized clinical trial. Eur Rev Med Pharmacol Sci. 2023;27:6058. 10.26355/eurrev_202307_32960
- Hayford FEA, Dolman RC, Ozturk M, Nienaber A, Ricci C, et al. Adjunct n-3 Long-Chain Polyunsaturated Fatty Acid Treatment in Tuberculosis Reduces Inflammation and Improves Anemia of Infection More in C3HeB/FeJ Mice With Low n-3 Fatty Acid Status Than Sufficient n-3 Fatty Acid Status. Front Nutr. 2021;8:695452. 10.3389/fnut.2021.695452
- Nienaber A, Baumgartner J, Dolman RC, Ozturk M, Zandberg L, et al. Omega-3 Fatty Acid and Iron Supplementation Alone, but Not in Combination, Lower Inflammation and Anemia of Infection in -Infected Mice. Nutrients. 2020;12. 10.3390/nu12092897
- Wu CYC, Lopez-Toledano MA, Daak AA, Clemons GA, Citadin CT, et al. SC411 treatment can enhance survival in a mouse model of sickle cell disease. Prostaglandins Leukot Essent Fatty Acids. 2020;158:102110. 10.1016/j.plefa.2020.102110
- Morsy KH, Zaghloul A, Mahmoud M. Can eicosapentaenoic acid maintain the original ribavirin dose or affect the response during the treatment course of chronic hepatitis C virus (HCV) patients?. Turk J Gastroenterol. 2016;27:55. 10.5152/tjg.2015.150280
- Malan L, Baumgartner J, Calder PC, Zimmermann MB, Smuts CM. n-3 Long-chain PUFAs reduce respiratory morbidity caused by iron supplementation in iron-deficient South African schoolchildren: a randomized, double-blind, placebo-controlled intervention. Am J Clin Nutr. 2015;101:668. 10.3945/ajcn.113.081208
- Suzuki M, Inage E, Minowa K, Saito N, Naritaka N, et al. Prophylaxis for ribavirin-related anemia using eicosapentaenoic acid in chronic hepatitis C patients. Pediatr Int. 2012;54:528. 10.1111/j.1442-200X.2012.03603.x
- Takaki S, Kawakami Y, Imamura M, Aikata H, Takahashi S, et al. Eicosapentaenoic acid could permit maintenance of the original ribavirin dose in chronic hepatitis C virus patients during the first 12 weeks of combination therapy with pegylated interferon-alpha and ribavirin. A prospective randomized controlled trial. Intervirology. 2007;50:439. 10.1159/000114718
- Seki R, Okamura T, Ide T, Kage M, Sata M, et al. Impaired filterability of erythrocytes from patients with chronic hepatitis C and effects of eicosapentaenoic acid on the filterability. J Physiol Sci. 2007;57:43.
- Hino K, Murakami Y, Nagai A, Kitase A, Hara Y, et al. Alpha-tocopherol [corrected] and ascorbic acid attenuates the ribavirin [corrected] induced decrease of eicosapentaenoic acid in erythrocyte membrane in chronic hepatitis C patients. J Gastroenterol Hepatol. 2006;21:1269.
- Ren H, Obike I, Okpala I, Ghebremeskel K, Ugochukwu C, et al. Steady-state haemoglobin level in sickle cell anaemia increases with an increase in erythrocyte membrane n-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids. 2005;72:415.
- Ide T, Okamura T, Kumashiro R, Koga Y, Hino T, et al. A pilot study of eicosapentaenoic acid therapy for ribavirin-related anemia in patients with chronic hepatitis C. Int J Mol Med. 2003;11:729.
- Kumaratilake LM, Robinson BS, Ferrante A, Poulos A. Antimalarial properties of n-3 and n-6 polyunsaturated fatty acids: in vitro effects on Plasmodium falciparum and in vivo effects on P. berghei. J Clin Invest. 1992;89:961.
- Sultanov R, Ermolenko E, Poleschuk T, Denisenko Y, Kasyanov S. Action of alkyl glycerol ethers and n-3 polyunsaturated fatty acids diet on hematological parameters of blood and liver plasmalogen level in aged rats. J Food Sci. 2021;86:2727. 10.1111/1750-3841.15756
- Freitas RDS, Muradás TC, Dagnino APA, Rost FL, Costa KM, et al. Targeting FFA1 and FFA4 receptors in cancer-induced cachexia. Am J Physiol Endocrinol Metab. 2020;319:E877. 10.1152/ajpendo.00509.2019
- Smuts CM, Matsungo TM, Malan L, Kruger HS, Rothman M, et al. Effect of small-quantity lipid-based nutrient supplements on growth, psychomotor development, iron status, and morbidity among 6- to 12-mo-old infants in South Africa: a randomized controlled trial. Am J Clin Nutr. 2019;109:55. 10.1093/ajcn/nqy282
- Daak AA, Dampier CD, Fuh B, Kanter J, Alvarez OA, et al. Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial). Blood Adv. 2018;2:1969. 10.1182/bloodadvances.2018021444
- Wang H, Shi P, Huang C, Liu Q. Maresin 1 ameliorates iron-deficient anemia in IL-10(-/-) mice with spontaneous colitis by the inhibition of hepcidin expression though the IL-6/STAT3 pathway. Am J Transl Res. 2016;8:2758.
- Shidfar F, Amani S, Vafa M, Shekarriz R, Hosseini S, et al. Effects of Iron Supplementation With and Without Docosahexaenoic Acid on the Cardiovascular Disease Risk Based on Paraoxonase-1, hs-CRP, and ApoB/ApoA-I Ratio in Women with Iron Deficiency Anemia. Biol Trace Elem Res. 2016;169:34. 10.1007/s12011-015-0383-7
- Wandersee NJ, Maciaszek JL, Giger KM, Hanson MS, Zheng S, et al. Dietary supplementation with docosahexanoic acid (DHA) increases red blood cell membrane flexibility in mice with sickle cell disease. Blood Cells Mol Dis. 2015;54:183. 10.1016/j.bcmd.2014.11.004
